托伐普坦治疗伴低钠血症的慢性心力衰竭临床疗效分析

Clinical analysis of topaplatin in the treatment of chronic heart failure with hyponatremia

目的:观察托伐普坦治疗伴低钠血症的慢性心力衰竭的临床疗效。方法:2018年12月-2020年6月收治伴低钠血症的慢性心力衰竭患者86例,随机分为两组,各43例。对照组给予常规抗心衰治疗;试验组在常规抗心衰治疗基础上加用口服托伐普坦治疗。比较两治疗效果。结果:试验组左心室射血分数(LVEF)、脑钠肽(BNP)、血钠离子浓度、24 h尿量水平均优于对照组,差异有统计学意义(P<0.05);试验组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。试验组出现轻微口干症状仅1例。结论:托伐普坦能改善心力衰竭患者的临床症状,明显提高心缓解率。

Objective:To observe the clinical efficacy of topaplatin in the treatment of chronic heart failure with hyponatremia.Methods:From December 2018 to June 2020,86 patients with chronic heart failure with hyponatremia were selected,they were randomly divided into the two groups with 43 cases in each group.The control group was treated with routine anti-heart failure therapy.The experimental group was treated with oral topaplatin on the basis of routine anti-heart failure treatment.The effects of the two treatments were compared.Results:The levels of left ventricular ejection fraction(LVEF),brain natriuretic peptide(BNP),and 24 h urine volume in the experimental group were better than those in the control group,the difference was statistically significant(P<0.05).The total effective rate in the experimental group was higher than that in the control group,the difference was statistically significant(P<0.05).There was only 1 case of mild dry mouth in the experimental group.Conclusion:Tovaptan can improve the clinical symptoms of patients with heart failure and significantly improve the cardiac remission rate.